Christopher Posner, President and CEO at Cara Therapeutics, Inc. (CARA), sold 4,191 shares at $11.80 ($49K) on 2023-02-02, disclosed to the SEC on 2023-02-03.
Scheduled sale ($49k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CARA | SELL | 2024-11-06 | $1K | — | Filing → |
| CARA | SELL | 2024-08-02 | $1K | — | Filing → |
| CARA | SELL | 2024-05-06 | $3K | — | Filing → |